InClinica CEO to Speak at Biocom’s First “Concept to Commercialization” Presentation

Press Releases

InClinica CEO to Speak at Biocom’s First “Concept to Commercialization” Presentation

James Nolan kicks off series with lecture on current state of CRO model

PHILADELPHIA (June 6, 2017) – InClinica, a global, clinical CRO, announced that CEO James Nolan was invited to kick off Biocom’s presentation series, “Concept to Commercialization,” with a special lecture on Wednesday, June 14 in San Diego.

Nolan’s lecture, titled “Why the Current CRO Model May Be Failing Developers, Investors and Patients,” will provide an in-depth analysis of the issues CROs face in this emerging landscape and how CROs can separate themselves in a highly competitive industry. He will also discuss key issues complicating the concept to commercialization path for drug developers.

“The healthcare industry has long needed new CRO models that will benefit developers, investors and – most importantly – patients,” said Nolan. “The start of this series comes at a much-needed time, and will hopefully help industry players understand the importance of new CRO approaches. I am honored to have the opportunity to kick off this incredible series, and look forward to opening the discussion on how we can help CROs reach their fullest potential.”

With more than 900 members and staff around the world, Biocom is the largest advocate group for the life science sector in California. To register for the lecture or learn more information, please visit: https://www.biocom.org/s/EventDetail?event=CRO-June.

About InClinica

InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in Israel, Malaysia/Singapore., the U.K., and throughout Europe.